Tandem Labs

Tandem Labs (now Covance) is a prominent bioanalytical service provider operating in the pharmaceutical industry. Founded in 1995 and headquartered in the United States, the company received its last investment of $18.80M in a Series A investment at 23 June 2005 from DW Healthcare Partners. Tandem Labs prides itself on offering cutting-edge technology and services aimed at supporting small and large-molecule development efforts for discovery, pre-clinical, and clinical studies. The company differentiates itself through its scientific expertise, responsive project management staff, structured method development, on-time metrics, and a strong regulatory history. The goal is to ease the workload of clients and shorten development timelines. Tandem Labs is now under the umbrella of Laboratory Corporation of America® Holdings, an S&P 500 company, and an influential player in the health care diagnostics industry. It provides comprehensive clinical laboratory services through LabCorp Diagnostics and end-to-end drug development support through Covance Drug Development. With combined revenue in excess of $8 billion in 2013 and over 48,000 employees in over 60 countries, LabCorp offers innovative solutions to healthcare stakeholders, including physicians, patients, consumers, biopharmaceutical companies, government agencies, managed care organizations, hospitals, and clinical labs. In conclusion, Tandem Labs, now operating under Covance, showcases a strong history and alignment with an influential parent company, enhancing its position as a leading player in the bioanalytical and pharmaceutical service industry.